company background image
4536 logo

Santen Pharmaceutical TSE:4536 Stock Report

Last Price

JP¥1.88k

Market Cap

JP¥662.0b

7D

1.2%

1Y

38.2%

Updated

30 Aug, 2024

Data

Company Financials +

Santen Pharmaceutical Co., Ltd.

TSE:4536 Stock Report

Market Cap: JP¥662.0b

4536 Stock Overview

Engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally.

4536 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance1/6
Financial Health6/6
Dividends5/6

Santen Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Santen Pharmaceutical
Historical stock prices
Current Share PriceJP¥1,876.50
52 Week HighJP¥1,878.50
52 Week LowJP¥1,255.00
Beta0
11 Month Change3.79%
3 Month Change15.26%
1 Year Change38.23%
33 Year Change9.99%
5 Year Change4.66%
Change since IPO506.63%

Recent News & Updates

Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)

Aug 31
Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)

Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 08
Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)

Aug 31
Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)

Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 08
Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next

Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares

Jun 25
Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares

Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

May 11
Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?

May 08
Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?

Shareholder Returns

4536JP PharmaceuticalsJP Market
7D1.2%0.9%1.1%
1Y38.2%21.0%13.7%

Return vs Industry: 4536 exceeded the JP Pharmaceuticals industry which returned 20.9% over the past year.

Return vs Market: 4536 exceeded the JP Market which returned 13.7% over the past year.

Price Volatility

Is 4536's price volatile compared to industry and market?
4536 volatility
4536 Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement6.3%
10% most volatile stocks in JP Market10.1%
10% least volatile stocks in JP Market3.4%

Stable Share Price: 4536 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4536's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
18903,744Takeshi Itowww.santen.com

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension.

Santen Pharmaceutical Co., Ltd. Fundamentals Summary

How do Santen Pharmaceutical's earnings and revenue compare to its market cap?
4536 fundamental statistics
Market capJP¥662.02b
Earnings (TTM)JP¥26.85b
Revenue (TTM)JP¥304.35b

24.7x

P/E Ratio

2.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4536 income statement (TTM)
RevenueJP¥304.35b
Cost of RevenueJP¥125.24b
Gross ProfitJP¥179.11b
Other ExpensesJP¥152.26b
EarningsJP¥26.85b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)76.11
Gross Margin58.85%
Net Profit Margin8.82%
Debt/Equity Ratio0%

How did 4536 perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

45%

Payout Ratio

Does 4536 pay a reliable dividends?

See 4536 dividend history and benchmarks
When do you need to buy 4536 by to receive an upcoming dividend?
Santen Pharmaceutical dividend dates
Ex Dividend DateSep 27 2024
Dividend Pay DateDec 02 2024
Days until Ex dividend27 days
Days until Dividend pay date93 days

Does 4536 pay a reliable dividends?

See 4536 dividend history and benchmarks